RxDoctor Payments Data

Evelyn Butler

Psychiatric/Mental Health · Gainesville, FLNPI 1093585754

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 51 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$361
  • AbbVie$321
  • Alkermes, Inc.$137
  • Vanda Pharmaceuticals Inc.$123
  • E.r. Squibb & Sons, L.L.C.$85
  • Teva Pharmaceuticals USA, Inc.$85
  • plus $123 from 3 others

What the payments were for

  • Food & beverage$1,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 60th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$7,475
Medicare patients
38
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate36$120,995
IngrezzaValbenazine Tosylate11$98,972
VraylarCariprazine Hcl62$95,169
AristadaAripiprazole Lauroxil12$40,574
RexultiBrexpiprazole22$34,569
Aripiprazole68$4,884
Quetiapine Fumarate ErQuetiapine Fumarate73$4,439
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,915
Ziprasidone Hcl32$1,328
Buspirone Hcl90$1,307
Quetiapine Fumarate55$1,252
Mirtazapine61$1,186
Hydroxyzine Hcl53$1,088
Divalproex Sodium35$1,086
Lamotrigine95$1,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$47$98,97211 claims
AbbVieVraylar$321$95,16962 claims
Alkermes, Inc.Aristada$137$40,57412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →